FDA approves Protein Sciences' quadrivalent influenza vaccine

Protein Sciences reports that FDA has approved its quadrivalent influenza vaccine (Flublok). According to the company, this is the first and only high antigen content four-strain vaccine approved by FDA.

Protein Sciences reports that FDA has approved its quadrivalent influenza vaccine (Flublok). According to the company, this is the first and only high antigen content four-strain vaccine approved by FDA. The vaccine has three times more active ingredient than other four-strain vaccines, Protein Sciences said, which makes it a good choice for older adults and those with compromised immune systems. The vaccine is approved for individuals aged 18 years and older. It is made without infectious influenza virus, antibiotics, eggs, thimerosal, preservatives, gelatin, or latex. Flublok will be available in early 2017 in pre-filled syringes, Protein Sciences said.